RxDoctor Payments Data

Jagga Alluri, MD

Neurology · Forest Hills, NYNPI 1053360008

Payments from drug & device makers

$64,136in general payments, 2019–2025

Across 1,402 payments — averaging $45.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • UCB, Inc.$2K
  • Eisai Inc.$2K
  • Biogen$1K
  • Neurelis, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$35,02255%
  • Food & beverage$28,88245%
  • Education$2310%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)252$40,620
UCB, Inc.136$1,689
Eisai Inc.59$1,681
Biogen92$1,374
Neurelis, Inc.47$1,328
Teva Pharmaceuticals USA, Inc.81$1,267
Scilex Pharmaceuticals Inc.77$1,095
AstraZeneca(2 entities)30$1,078
Pfizer52$1,072
SK Life Science, Inc.42$901
Amgen(2 entities)33$855
Sanofi39$801
Argenx US, Inc.32$790
Lilly USA, LLC31$771
MDD US Operations, LLC25$770
Neurocrine Biosciences, Inc.30$709
Bristol Myers Squibb37$627
Lundbeck LLC32$614
Novartis38$546
Acorda Therapeutics, Inc24$477
Medtronic(2 entities)9$357
Amneal Pharmaceuticals LLC16$325
Abbott5$320
Adamas Pharmaceuticals, Inc.15$297
ANI Pharmaceuticals, Inc.19$296
Boston Scientific3$258
Otsuka America Pharmaceutical, Inc.2$258
Kyowa Kirin, Inc.17$245
Acadia Pharmaceuticals Inc17$234
Merz Pharmaceuticals, LLC17$232
Mallinckrodt Hospital Products Inc.6$219
E.r. Squibb & Sons, L.L.C.5$203
Grifols USA, LLC8$185
Biohaven Pharmaceuticals, Inc.5$169
Ipsen Biopharmaceuticals, Inc3$149
Biohaven Pharmaceutical Holding Company Ltd.9$131
Supernus Pharmaceuticals, Inc.6$126
Bayer1$125
Sumitomo Pharma America, Inc.5$109
Vanda Pharmaceuticals Inc.4$95
Axsome Therapeutics, Inc.3$75
Vertical Pharmaceuticals, LLC4$69
Assertio Therapeutics, Inc.3$56
Bausch Health US, LLC3$55
Corium, LLC5$51
TG Therapeutics, Inc.2$47
Currax Pharmaceuticals LLC3$47
Livanova USA, Inc.2$43
Banner Life Sciences, LLC3$43
Avion Pharmaceuticals2$30
CSL Behring1$28
Redhill Biopharma Inc.1$28
Averitas Pharma Inc.1$22
EMD Serono, Inc.1$22
Jazz Pharmaceuticals Inc.1$20
Catalyst Pharmaceuticals, Inc.1$19
Almatica Pharma LLC1$18
Genentech USA, Inc.1$17
Impel Pharmaceuticals Inc.1$17
Novo Nordisk1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,136 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$307,250
Medicare patients
351
Services billed
3,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant119$153,749
Nurtec OdtRimegepant Sulfate57$68,111
OngentysOpicapone95$64,355
QuliptaAtogepant61$62,869
AustedoDeutetrabenazine13$59,390
ZtlidoLidocaine115$47,295
RexultiBrexpiprazole25$39,529
BotoxOnabotulinumtoxina35$37,582
InbrijaLevodopa13$27,199
AptiomEslicarbazepine Acetate17$20,172
Aimovig AutoinjectorErenumab-Aooe17$14,761
Doxepin Hcl74$13,514
FycompaPerampanel12$6,976
Memantine Hcl530$6,318
Memantine Hcl ErMemantine Hcl96$6,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$40,620$254,200215 claims
PfizerNurtec Odt$1,072$68,11157 claims
Neurocrine Biosciences, Inc.Ongentys$709$64,35595 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,267$59,39013 claims
Scilex Pharmaceuticals Inc.Ztlido$1,095$47,295115 claims
Otsuka America Pharmaceutical, Inc.Rexulti$258$39,52925 claims
Acorda Therapeutics, IncInbrija$477$27,19913 claims
Eisai Inc.Fycompa$1,681$6,97612 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$325$45111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in Forest Hills

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →